1. Introduction
===============

Cancer, traditionally considered a genetic disease, is now thought to represent the result of a mixture of genetic and epigenetic events, which variously influence the degree of its biological aggressiveness and metastasizing ability \[[@b1-ijms-13-11044]--[@b8-ijms-13-11044]\]. The potentially reversible nature of the epigenetic changes has led to hypothesize the use of epigenetic modulators for the establishment of alternative anticancer therapies \[[@b9-ijms-13-11044]--[@b11-ijms-13-11044]\]. The epigenetic information includes DNA methylation, RNA-mediated silencing and histone modifications and, although DNA methylation and histone acetylation are among the most frequent epigenetic modifications observed both in normal and neoplastic cells, the disruption of any of these three distinct and mutually reinforcing epigenetic mechanisms might lead to an inappropriate gene expression, resulting in cancer development and other "epigenetic diseases" \[[@b9-ijms-13-11044],[@b12-ijms-13-11044]\]. Epigenetic alterations, especially histone modifications, influence cellular metabolism mainly affecting the chromatin structure. Great attention has been recently focused on the role of chromatin dynamics as a critical determinant in many nuclear events and in pathological conditions such as tumour development and progression \[[@b13-ijms-13-11044]--[@b15-ijms-13-11044]\]. Within the cell, the nuclear DNA is tightly packaged in the chromatin structure. The nucleosome is the fundamental unit of chromatin and its core particle is composed of an octamer of the four core histones (H3, H4, H2A, H2B), around which 147 base pairs of DNA are wrapped. DNA packaging follows several orders of wrapping and is fundamental for the maintenance of the genome stability regulating the DNA-based activities as DNA replication, transcription and repair. Histone chaperons play a critical role in maintaining and regulating chromatin structure by driving histones deposition. CAF-1 (Chromatin Assembly Factor-1) is a heterotrimeric histone chaperone formed by p48, p60 and p150 proteins that plays a pivotal role in the regulation of chromatin assembly coupled to DNA replication and repair \[[@b16-ijms-13-11044]\]. During the S phase of the eukaryotic cell cycle, the newly replicated DNA is rapidly assembled into chromatin. CAF-1 mediates the deposition of newly synthesised histones H3.1 and H4 onto nascent DNA \[[@b17-ijms-13-11044]\] and their assembly into nucleosomes, by association with PCNA \[[@b18-ijms-13-11044]\]. In the same way, CAF-1 complex mediates the assembly of nucleosomes following DNA damage repair. Several reports have recently shown that a deregulated expression of CAF-1 p60 is linked to the neoplastic progression of most of the human solid malignancies \[[@b17-ijms-13-11044],[@b19-ijms-13-11044]--[@b22-ijms-13-11044]\]. In particular, the CAF-1 p60 subunit has been found overexpressed in breast, oral, prostate, and salivary gland carcinomas, as well as in skin melanoma \[[@b23-ijms-13-11044]--[@b28-ijms-13-11044]\]. Interestingly, CAF-1 p60 expression levels are significantly correlated with the biological aggressiveness of tumours, metastasizing behaviour and worse prognosis \[[@b23-ijms-13-11044]--[@b28-ijms-13-11044]\]. This suggested CAF-1 p60 could have a promising role as a new sensible "transversal" prognostic marker for human tumours, apparently unrelated to their histogenesis. To date the *on-site* expression of CAF-1 p60 in human tumours has been mostly performed on routine sections of paraffinized tissues; in addition, fine needle aspirates have also been used in order to evaluate CAF-1 p60 expression at least in breast \[[@b27-ijms-13-11044]\] and salivary gland tumours \[[@b23-ijms-13-11044]\]. In the present study, we evaluated the immunohistochemical expression of CAF-1 p60 on tissue microarray (TMA) sections generated by taking core biopsies from the same tumour series previously evaluated for this protein. The aim of our study is to assess the degree of agreement in the extent and intensity of CAF-1 p60 immunoreactivity between the values observed in TMAs and routine sections. As is well known, TMA constitutes a powerful high-throughput methodology which has been increasingly used for validation of new cancer biomarkers, and hopefully it could represent a valuable tool for the rapid screening for CAF-1 p60 expression in malignant tumours, in the context of their prognostic evaluation.

2. Results
==========

2.1. CAF-1 p60 in Normal Tissue
-------------------------------

CAF-1 p60 immunostaining showed a focal, scattered, nuclear positivity in TMAs as in routine sections of normal tissue specimens. CAF-1 p60 positive cells were found almost always localized in the regenerative compartment: from 0 to \<10% of cells from the basal layer of epidermis and oral mucosal epithelium keratinocytes, of melanocytes at the dermal-epidermal junction, or of secretory cells of prostate and salivary glands showing, in fact, CAF-1 p60 positivity at immunostaining.

2.2. CAF-1 p60 in Tumours
-------------------------

All the evaluated malignant tumours showed CAF-1 p60 overexpression ([Figure 1](#f1-ijms-13-11044){ref-type="fig"}, [Tables 1](#t1-ijms-13-11044){ref-type="table"}--[7](#t7-ijms-13-11044){ref-type="table"}). Representative images of CAF-1 p60 expression in normal tissues are shown in [Figure 2](#f2-ijms-13-11044){ref-type="fig"}. In detail, a moderate expression (++) of CAF-1 p60 was found in 13 Oral Squamous Cells Carcinoma (OSCC) (3 G1, 8 G2, 2 G3), 22 Prostate Cancer (PC) (1 with Gleason score \<7, 15 with a Gleason score equal to 7, of which 5 with a primary pattern of 4 and 10 with a primary pattern of 3, and 6 with Gleason score \>7), 14 Skin Melanoma (SM) (4 with Breslow vertical phase thickness \<1.00 mm, 3 comprised between 1.01 and 2.00, 4 comprised between 2.01 and 4.00 and 3 \> 4.00 mm), 22 Salivary Gland Tumour (SGT), of which 1 polymorphous low-grade carcinoma (PLGC), 3 acinic cell carcinomas (AC), 3 adenoid cystic carcinomas (ACC), 11 muco-epidermoid carcinomas (4 low grade, 3 intermediate-grade and 4 high-grade tumours), and 4 cases of carcinoma ex-PA (CXPA) 26 Laryngeal Squamous Cell Carcinoma (LSCC) (6 G1, 6 G2, 14 G3) and 28 Skin Squamous Cell Carcinoma (SSCC) (8 G1, 10 G2, 10 G3); as a high level of expression (+++) was observed in the remaining 17 OSCC (7 G1, 7 G2 and 3 G3), 8 PC (2 with Gleason score \<7, 3 with a Gleason score equal to 7, with a primary pattern of 4, and 3 with Gleason score \>7), 16 SM (2 with Breslow vertical phase thickness \<1.00 mm, 5 comprised between 1.01 and 2.00, 6 comprised between 2.01 and 4.00 and 3 \> 4.00 mm), 7 cases of malignant SGT, of which 1 adenoid cystic carcinomas (ACC), 5 muco-epidermoid carcinomas (1 low grade, 3 intermediate-grade and 1 high-grade tumours) and 1 case of CXPA, 4 LSCC (1 G1, 1 G2, 2 G3) and 2 SSCC (1 G2 and 1 G3). The values found on the whole sections of OSCC, PC, SGTs and SM were in agreement with those already reported in the literature \[[@b23-ijms-13-11044]--[@b26-ijms-13-11044]\]. The evaluation of the immunohistochemical expression of CAF-1 p60 on TMA sections of the same tumour series gave rise to quite similar results, with an excellent level of agreement for both the intra- and inter-observer evaluation of the expression of CAF-1 p60 on the whole sections and TMAs (K-coefficient: 0.8018 for OSCC; 0.8148 for PC; 0.8018 for SM; 0.8529 for SGT; 0.8696 for LSCC, 0.8076 for SSCC) ([Table 8](#t8-ijms-13-11044){ref-type="table"}, [Figure 3](#f3-ijms-13-11044){ref-type="fig"}). According to univariate statistical analysis, both on routine whole sections and on TMA, no statistical correlation was found between CAF-1 p60 expression, age and sex of patients (data not shown).

Irrespective of the tumour histogenesis, CAF-1 p60 showed high levels of expression in all evaluated tumours (OSCC, PC, SM, SGTs and LSCC and SSCC) with the highest values in cases showing adverse events during the follow up (relapse, lymph node and/or distant metastasis, death from disease). Correlation between CAF-1 p60 expression and adverse events at follow-up proved to be statistically significant, as shown by Kaplan-Meier curves in [Figure 4](#f4-ijms-13-11044){ref-type="fig"}.

3. Discussion
=============

The high concordance in the evaluation of CAF-1 p60 expression between the TMAs and the whole section specimens, in agreement with data reported from similar comparative studies in literature \[[@b29-ijms-13-11044]--[@b33-ijms-13-11044]\], supports the idea that the TMA technique is a very useful tool for novel diagnostic and/or prognostic marker screening in tumours. The TMA method, used in the majority of pathology laboratories, is a standardized technology based on the original technique proposed by Wan *et al.* and further modified by Kononen in 1998 \[[@b34-ijms-13-11044],[@b35-ijms-13-11044]\]. Recently, many studies, comparing the data obtained from conventional and TMA sections, validated the use of TMAs as a useful tool for diagnostic and/or prognostic biomarkers screening in several tumours, such as oral and oesophageal squamous cell carcinomas \[[@b36-ijms-13-11044],[@b37-ijms-13-11044]\], ovarian cancers \[[@b38-ijms-13-11044]\], breast carcinomas \[[@b39-ijms-13-11044]\], and peripheral nerve malignant sheath tumours \[[@b40-ijms-13-11044]\]. This report constitutes the first study in which the TMA method was used to evaluate the immunohistochemical expression of CAF-1 p60 in different human malignancies and correlated with adverse clinical outcome. Our data obtained on sections of TMAs confirmed that CAF-1 p60 protein is increased in all the evaluated tumours, from those that have already been reported in the literature, such as MM, PC, OSCC and OSGT, to the newly investigated LSCC and SSCC. Recently, Polo and coll. published a study showing the overexpression of CAF/p60 in a series of different human malignancies \[[@b28-ijms-13-11044]\]. In the present study, we have shown that in our selected series of patients, the higher expression of CAF-1 p60 was significantly associated to a more aggressive biological behaviour of tumours, confirming the idea that the increase of CAF-1 p60 expression is strictly correlated with the cancer progression and the metastasizing ability of transformed cells, irrespective of their histological type and differentiation. Notably, our data strongly suggest that the use of TMAs is a reliable technique for the immunohistochemical assessment of CAF-1 p60 expression, and it may be proposed as an efficient, time- and cost-effective, evaluation of this new promising biomarker of the aggressiveness of malignant tumours \[[@b41-ijms-13-11044]--[@b43-ijms-13-11044]\]. Moreover, as multiple recent reports have indicated the immunohistochemical evaluation of CAF-1 p60 expression may add important information to the prognostic prevision of most human solid malignancies; the finding that this evaluation can be performed on TMAs with results quite similar to those derived from the immunostaining of routine whole tissue sections is extremely exciting, in terms of use of both pathologists' time and resources. In addition, the TMA assembly procedure used for this study is easy to perform and cheaper than that obtained with the use of the expensive automated tissue array devices. For this reason, the manual TMA technique can be used even in small pathology laboratories with a limited budget, representing the ideal pre-requisite for a screening technology. Using 3 mm diameter tissue cores we can strongly reduce the bias due to the reduced amount of tissue, especially when compared to the TMA made of small cores obtained with automatized devices from hundreds of individual specimens. In addition, the time- and cost-efficient manual TMAs based on large 3 mm cores, allow a better evaluation of both the histological characteristics, as well as the extent and pattern of the immunostaining signal distribution. A single 3 mm-diameter tissue core provides, in fact, more than twice the total tumour area covered by the three small cores obtained with the automatized systems. TMA is a time- and cost-efficient method of evaluating the immunohistochemical expression of several proteins in a large number of tumours. The TMA technique leads, in fact, to great economy in time, reagents and tissue specimens and facilitates the rapid standardization and introduction of new antibodies into routine diagnostic immunohistochemistry, allowing pathologists to quickly evaluate hundreds of cores of selected tissue samples \[[@b44-ijms-13-11044],[@b45-ijms-13-11044]\]. Moreover, the TMA technique provides a great opportunity to easily analyse, store and share IHC data on a large number of samples over a long period of time when combined, with the digital management of slides, offering a cost-efficient alternative to routine diagnostics.

4. Experimental Section
=======================

In the present study, we selected a total of 180 human tumours diagnosed at the Department of Biomorphological and Functional Sciences, Pathology Section, University "Federico II" of Naples, Italy, from 1 January 2000 to 31 December 2009. The selected cases encompassed 30 oral squamous cell carcinomas (OSCC), 30 prostate carcinomas (PC), 30 salivary gland tumours (SGT) and 30 skin melanomas (SM), all belonging to the same selected series of patients who had previously been screened for CAF-1 p60 by immunohistochemistry \[[@b23-ijms-13-11044]--[@b26-ijms-13-11044]\] and 30 laryngeal squamous cell carcinomas (LSCC) and 30 skin squamous cell carcinomas (SSCC), that had never been evaluated for CAF-1 p60 expression. The clinic-pathological features of all patients are summarized in [Table 1](#t1-ijms-13-11044){ref-type="table"}. For each patient, the tumour stage class was determined according to the American Joint Committee, AJCC \[[@b46-ijms-13-11044]\]. The study was performed according to the Declaration of Helsinki and in agreement with Italian law that, due to the topics of this research, does not provide a specific Ethical Committee assent.

4.1. TMAs Construction and Immunohistochemistry
-----------------------------------------------

Two pathologists (SS and MM) reviewed the whole routine haematoxylin-eosin (H & E) sections to confirm the original diagnosis and to mark the most representative tumour areas useful for the TMA construction. From one paraffin block of each tumour, a 4-μm thick section was cut and mounted on a slide pre-treated for immunohistochemical evaluation of CAF-1 p60 expression. Then, for all selected cases, the tumour area for TMA construction was identified on the same paraffin donor blocks under the guidance of the corresponding previously marked H & E section and punched by a manual tissue-array instrument (Tissue-Tek Quick-Ray, Sakura Finetek, Torrance, CA, USA). The tissue cores (3 mm in diameter) were carefully transferred to the recipient paraffin blocks with 30 holes each. The filled recipient blocks were then placed on a metal base mould. The paraffin-embedding was then carried-out, by heating the blocks at 42 °C for 10 min, and flattening their surface by pressing a clean glass slide on them. As a result, a TMA was built for each cancer histotype (OSCC, LSCC, PC, SSCC, SGT and MM). In addition, cores of non-neoplastic oral and laryngeal mucosa, salivary glands, prostate tissue, and skin were included in a further tissue array block to pursue normal controls. After chilling the tissue arrays to −10 °C for 30 min, according to the technique described two 4-μm sections were cut from each TMA using an ordinary microtome \[[@b44-ijms-13-11044]\]. The first section was stained with H&E to confirm the presence of tumour and the integrity of tissues. The second section was mounted on a super frost slide (Microm, Walldorf, Germany) for the immunohistochemical evaluation of CAF-1 p60 expression. The slides were de-waxed by heating at 55 °C for 30 min followed by 3 washes, 5 min each, with xylene, and rehydrated by 5-min washes with 100%, 95%, and 80% ethanol up to pure distilled water. The Antigen retrieval was obtained by heating the sections at 95 °C for 30 min in 10 mM sodium citrate (pH 6.0). Endogenous peroxidase activity was blocked by the incubation in 3% hydrogen peroxide for 30 min. The background reactivity was removed using the universal blocking serum (Dako Diagnostics, Glostrup, Denmark) for 30 min at room temperature. At this point, the slides were incubated overnight at 4 °C with anti-CAF-1 p60 antibody (SS53-ab8133, Abcam, Cambridge, MA, USA, diluted 1:300) \[[@b23-ijms-13-11044]--[@b26-ijms-13-11044]\]. The incubation for 30 min with a biotin-labeled secondary antibody was then performed. The streptavidin-peroxidase (DAKO Diagnostics) was applied and developed using 3,3′-diaminobenzidine substrate (Vector Laboratories, Burlingame, CA, USA). After slight counterstaining with haematoxylin, the slides were dehydrated and mounted with cover slips for microscopic examination. Breast carcinoma sections were used as positive control. Negative controls were included incubating the sections with pre-immune serum instead of the antibody. The cells with a definite brown nuclear staining were judged positive for CAF-1 p60 antibody. The evaluation of nuclear CAF-1 p60 staining was blindly and independently examined in all TMA cores and in whole sections of the selected donor blocks. CAF-1 p60 expression was evaluated as the percentage of positive tumor cells among the total neoplastic cells present in at least 10 high power fields and graded semi-quantitatively according to an arbitrary scale, as follows: 0 (\<10% of positive cells); + (10% to \<20%); ++ (20% to \<30%); +++ (≥30% of positive cells) \[[@b23-ijms-13-11044]--[@b26-ijms-13-11044]\]. In case of discrepancy between the two pathologists, the immunostained slides were reviewed in a double viewing microscope to settle the discrepancy. Cores were considered lost if \<10% of cells contained tumour ("sampling error") or when \<10% of tissue was present ("absent core") \[[@b47-ijms-13-11044]\]. Immunohistochemistry was performed with the same end-quality both on whole sections and on TMA, without losing tissue cores during all the steps of the procedure.

4.2. Statistical Analysis
-------------------------

Statistical analysis was performed with SPSS package for Windows (release 17.0). The χ^2^ test was used to compare the quantitative differences of CAF-1 p60 staining in various stages of different tumours progression. The Kaplan-Meier curves were used to evaluate the disease free survival of patients grouped by CAF-1 p60 expression. A two-sided Log-rank test was used to compare Kaplan-Meier curves and to assess statistical significance. The *p-*value was considered significant if \<0.05. To determine the chance-corrected agreement between the immunohistochemical staining scores of TMA core and the whole sections, the Cohen's weighted kappa statistic was calculated. Chance-corrected agreement was considered poor if *K* \< 0.00, slight if *K* was between 0 and 0.20, fair if *K* was between 0.21 and 0.40, substantial if *K* was between 0.61 and 0.80, and almost perfect if *K* was \>0.80. The overall agreement was defined as the percentage of correct concordance between the TMA and the donor blocks from the total number of cases \[[@b48-ijms-13-11044]\].

5. Conclusions
==============

There is an urgent need for new, reliable prognostic markers to identify human cancers with an aggressive behaviour, and CAF-1 p60 proved to be a very promising candidate, as we have previously shown. So far, CAF-1 p60 expression assessment has been carried out mainly on whole tissue sections. The 3 mm cores TMA is a powerful, cost-effective, high-throughput methodology in the study of cancer, allowing simultaneous, highly accurate, assessment of different biomarkers within large numbers of tissue specimens. In the present study a high concordance was found between CAF-1 p60 assessment on TMAs and on routine tissue sections.

We strongly believe that the manual construction procedure of TMA will facilitate its set-up, easily allowing an enlargement of the amount of data concerning the role of CAF-1 p60 expression in human tumours, favouring the diffusion of this biomarker into the clinical setting.
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![Immunohistochemical staining for Chromatin Assembly Factor 1 (CAF-1 p60) (LSAB technique) (**a**) the design of tissue microarray technique (TMAs) (haematoxylin and eosin staining). Each slide contains 5 × 6 cores (30 cores) sampled from neoplastic tissues; (**b**,**c**) Oral Squamous Cell Carcinoma (OSCC), b: 25×, c: 250×; (**d**,**e**) Laryngeal Squamous Cell Carcinoma (LSCC), d: 25×, e: 250×; (**f**,**g**) Prostate Carcinoma (PC), f: 25×, g: 250×; (**h**,**i**) Skin Squamous Cell Carcinoma (SSCC), h: 25×, i: 250×; (**l**,**m**) Skin Melanoma (SM), l: 25×, m: 250×; (**n**,**o**) Salivary gland tumours (SGT), n: 25×; o: 250×. Ki67 immunohistochemical staining for Ki67 (LSAB technique) is shown in **p** (OSCC), **q** (LSCC), **r** (PC), **s** (SSCC), **t** (SM) and **u** (SGT).](ijms-13-11044f1){#f1-ijms-13-11044}

![Immunohistochemical staining for CAF-1 p60 (LSAB technique) on normal tissues (**a**) Lower lip, muco-cutaneous junction (left: oral mucosa; right: skin); (**b**) Larynx: normal-to hyperplastic, with underlying infiltrating squamous cell carcinoma; (**c**) Salivary gland; (**d**) Skin (arrow heads indicate normal melanocytes negative to p60 immunostaining); (**e**) Prostate glands, normal to hyperplastic. The insert shows magnification of the marked area (white square).](ijms-13-11044f2){#f2-ijms-13-11044}

![Comparison of the percentage of labelled cells on TMA sections and whole-tissue sections (WS) for the CAF-1 p60 antibody. Scatter plots show a tight grouping of points when the percentage of labelled cells on TMA sections is plotted against the WS for the CAF-1 p60 antibody. The added lines are the lines of best fit, *R*^2^ values of linear regressions are shown. (**a**) Oral squamous cell carcinoma (OSCC); (**b**) prostate cancer (PC); (**c**) salivary gland tumour (SGT); (**d**) skin melanoma (SM); (**e**) laryngeal squamous cell carcinoma (LSCC); (**f**) skin squamous cell carcinoma (SSCC).](ijms-13-11044f3){#f3-ijms-13-11044}

![Kaplan-Meier plots showing disease free survival for OSCC, PC, SGT, SM, LSCC AND SSCC patients grouped by the level of expression of CAF-1 p60. Tumor samples were stratified in three categories (+, ++, and +++) based on intensity of CAF-1 p60 immunostaining. The comparison between survival curves and *p* value was determined by a two-sided log-rank test. (**a**) Oral squamous cell carcinoma (OSCC); (**b**) prostate cancer (PC); (**c**) salivary gland tumour (SGT); (**d**) skin melanoma (SM); (**e**) laryngeal squamous cell carcinoma (LSCC); (**f**) skin squamous cell carcinoma (SSCC).](ijms-13-11044f4){#f4-ijms-13-11044}

###### 

Clinical and pathological features of all examined patients.

  Histotype             *N*°                              *m*   *f*   Age Range (average)    F-up Range (average)      Grade             Outcome
  --------------------- --------------------------------- ----- ----- ---------------------- ------------------------- ----------------- ---------------------------------
  **OSCC**              30                                18    12    48--95 years (66.7)    4--120 months (49.23)     10 G1 (33%)       3 NED, 2 M, 1 D, 1 M,D, 3 R,M,D
  15 G2 (50%)           8 NED, 3 M,D, 2 R,D, 2 R,M,D                                                                                     
  5 G3 (17%)            2 NED, 1 M,D, 1 R,D, 1 R,M,D                                                                                     
                                                                                                                                         
  **PC**                30                                30    0     55--80 years (66.7)    30--64 months (40)        3 GS ≤ 6 (10%)    1 NED, 1 M, 1 M,D
  18 GS 7 (60%)         15 NED, 2 M, 1 M,D                                                                                               
  9 GS \> 8 (30%)       6 NED, 2 M, 1 M,D                                                                                                
                                                                                                                                         
  **SM**                30                                15    15    21--81 years (46.2)    1--22 years (8.67)        6 BT \< 1 (20%)   4 NED, 1 R, 1 N
  8BT 1.01--2 (27%)     3 NED, 3 N, 1 R,N, 1 N,M,D                                                                                       
  10 BT 2.01--4 (33%)   4 NED, 1 M, 2 N, 1 N,M, 2 N,M,D                                                                                  
  6 BT \> (20%)         3 NED, 2 N, 1 R,M,D                                                                                              
                                                                                                                                         
  **SGT**               30                                12    18    18--80 years (48.77)   12--200 months (67)       1 PLGC (3%)       1 NED
  4 ACC (13%)           3 NED, 1 M,R                                                                                                     
  16 MEC (54%)          12 NED, 3 R, 1 M                                                                                                 
  3 AC (10%)            3 NED                                                                                                            
  5 CXPA (17%)          4 NED; 1 R,N                                                                                                     
  1 PA (3%)             1 NED                                                                                                            
                                                                                                                                         
  **LSCC**              30                                30    0     38--76 years (63.3)    38--189 months (130.33)   7 G1 (23%)        6 NED, 1 M
  7 G2 (23%)            6 NED, 1 M                                                                                                       
  16 G3 (54%)           14 NED, 2 M                                                                                                      
                                                                                                                                         
  **SSCC**              30                                17    13    32--95 years (68.04)   12--223 months (138.83)   8 G1 (26%)        8 NED
  11 G2 (37%)           10 NED, 1 R,N                                                                                                    
  11 G3 (37%)           10 NED, 1 R                                                                                                      

GS: Gleason score; BT: Breslow thickness; NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease; N: nodes metastasis; OSCC: Oral Squamous Cell Carcinoma; PC: Prostate Carcinoma; SM: Skin Melanoma; SGT: Salivary Gland Tumour; LSCC: Laryngeal Squamous Cell Carcinoma; SSCC: Skin Squamous Cell Carcinoma.

###### 

Clinical and pathological features of the study population of OSCC, ordered by grading. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Grading   TNM Stage   WS CAF-1 p60   WS CAF-1 p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- --------- ----------- -------------- ------------------ --------------- ------------------- ----------
  m     95    SCC         1         I           ++             25                 ++              22                  17 NED
  m     64    SCC         1         I           ++             22                 ++              21                  21 NED
  f     81    SCC         1         I           ++             23                 ++              21                  4 NED
  m     49    SCC         1         I           +++            34                 +++             32                  43 D
  m     66    SCC         1         III         +++            39                 +++             33                  120 M
  m     49    SCC         1         III         +++            41                 +++             38                  79 M
  m     86    SCC         1         III         +++            42                 +++             40                  22 M,D
  m     75    SCC         1         IV          +++            45                 +++             38                  11 R,M,D
  m     56    SCC         1         IV          +++            47                 +++             39                  77 R,M,D
  f     68    SCC         1         III         +++            46                 +++             41                  88 R,M,D
  m     66    SCC         2         II          ++             23                 ++              23                  120 NED
  m     50    SCC         2         I           ++             22                 ++              21                  109 NED
  m     78    SCC         2         III         ++             25                 ++              23                  11 NED
  m     48    SCC         2         I           ++             21                 ++              21                  14 NED
  m     48    SCC         2         I           ++             24                 ++              23                  85 NED
  f     74    SCC         2         I           ++             26                 ++              21                  19 NED
  f     67    SCC         2         I           ++             22                 ++              22                  97 NED
  f     59    SCC         2         II          ++             24                 ++              23                  98 NED
  m     69    SCC         2         III         +++            35                 +++             34                  12 R,D
  m     58    SCC         2         IV          +++            36                 +++             31                  8 R,D
  f     77    SCC         2         I           +++            38                 +++             33                  114 M,D
  f     75    SCC         2         IV          +++            37                 +++             36                  27 M,D
  f     73    SCC         2         III         +++            41                 +++             38                  10 M,D
  m     65    SCC         2         III         +++            35                 ++              27                  20 R,M,D
  m     60    SCC         2         IV          +++            50                 +++             39                  24 R,M,D
  f     60    SCC         3         I           ++             26                 ++              23                  106 NED
  m     66    SCC         3         I           ++             22                 ++              21                  97 NED
  f     80    SCC         3         II          +++            35                 ++              28                  23 R,D
  m     63    SCC         3         III         +++            39                 ++              29                  17 M,D
  m     65    SCC         3         II          +++            41                 +++             38                  15 R,M,D

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Clinical and pathological features of the study population of PC, ordered by Gleason Score. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Gleason     TNM Stage   WS CAF-1 p60   WS CAF-1 p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- ----------- ----------- -------------- ------------------ --------------- ------------------- --------
  m     70    AC          5 (3 + 2)   pT2bN0      +++            36                 ++              28                  57 M
  m     51    AC          5 (3 + 2)   pT2bN0      +++            40                 +++             33                  50 M,D
  m     72    AC          6 (3 + 3)   pT2bN0      ++             23                 ++              22                  81 NED
  m     68    AC          7 (3 + 4)   pT3aN0      ++             25                 ++              25                  49 NED
  m     67    AC          7 (4 + 3)   pT3aNx      ++             27                 ++              26                  33 NED
  m     58    AC          7 (3 + 4)   pT2bN0      ++             24                 ++              21                  32 NED
  m     45    AC          7 (3 + 4)   pT2bN0      ++             23                 ++              23                  30 NED
  m     53    AC          7 (3 + 4)   pT2bN0      ++             24                 ++              22                  75 NED
  m     65    AC          7 (4 + 3)   pT4N1       +++            37                 +++             36                  49 M
  m     63    AC          7 (4 + 3)   pT3aN0      ++             24                 ++              23                  32 NED
  m     68    AC          7 (4 + 3)   pT3bN0      ++             26                 ++              25                  33 NED
  m     73    AC          7 (3 + 4)   pT3aN1      ++             23                 ++              22                  56 NED
  m     71    AC          7 (4 + 3)   pT3bN1      ++             26                 ++              25                  30 NED
  m     80    AC          7 (4 + 3)   pT3bN1      ++             24                 ++              20                  40 NED
  m     57    AC          7 (3 + 4)   pT2bN0      ++             21                 ++              21                  33 NED
  m     70    AC          7 (3 + 4)   pT2aN0      ++             25                 ++              23                  32 NED
  m     56    AC          7 (3 + 4)   pT2bN0      ++             23                 ++              22                  33 NED
  m     61    AC          7 (3 + 4)   pT2aN0      ++             25                 ++              24                  32 NED
  m     65    AC          7 (4 + 3)   pT3bN1      +++            41                 ++              29                  43 M,D
  m     60    AC          7 (3 + 4)   pT2aN0      ++             24                 ++              22                  33 NED
  m     62    AC          7 (4 + 3)   pT3aNo      +++            35                 +++             33                  64 M
  m     64    AC          8 (4 + 4)   pT2bN0      ++             23                 ++              21                  59 NED
  m     66    AC          8 (4 + 4)   pT3bN1      ++             26                 ++              22                  33 NED
  m     71    AC          8 (4 + 4)   pT3bN1      +++            42                 +++             38                  57 M,D
  m     60    AC          8 (4 + 4)   PT3aN0      ++             25                 ++              21                  33 NED
  m     70    AC          8 (4 + 4)   pT3bN0      ++             22                 ++              21                  32 NED
  m     74    AC          8 (4 + 4)   pT3aN0      ++             25                 ++              23                  32 NED
  m     64    AC          8 (4 + 4)   pT3bN0      +++            37                 +++             33                  48 M
  m     57    AC          8 (4 + 4)   pT3aN0      ++             24                 ++              22                  30 NED
  m     73    AC          8 (4 + 4)   pT2bN1      +++            35                 +++             32                  34 M

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Clinical and pathological features of the study population of SGT, ordered by histology subtype. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Grading        TNM Stage   WS CAF-1 p60   WS CAF-1 p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- -------------- ----------- -------------- ------------------ --------------- ------------------- ---------
  m     49    PLGC        \-             pT1N0M0     ++             24                 ++              22                  26 NED
  f     33    AC          \-             pT3N0M0     ++             25                 ++              21                  67 NED
  m     45    AC          \-             pT2NxM0     ++             26                 ++              24                  70 NED
  f     78    AC          \-             pT3NxM0     ++             21                 ++              20                  44 NED
  f     39    ACC         \-             pT2N0M0     ++             25                 +++             31                  29 NED
  f     41    ACC         \-             pT3N0M0     ++             26                 ++              24                  54 NED
  m     48    ACC         \-             pT4aNxM0    +++            39                 +++             37                  71 M,R
  f     63    ACC         \-             pT2NxM0     ++             25                 ++              22                  44 NED
  f     20    LG-MEC      low            pT1N0M0     ++             22                 ++              21                  49 NED
  f     57    LG-MEC      low            pT3N0M0     +++            32                 +++             31                  173 NED
  f     18    LG-MEC      low            pT2N0M0     ++             26                 ++              23                  92 NED
  f     40    LG-MEC      low            pT4aN0M0    ++             27                 ++              22                  69 NED
  f     62    LG-MEC      low            pT3NxM0     ++             23                 ++              22                  103 NED
  m     39    IG-MEC      intermediate   pT2N0M0     +++            37                 +++             35                  140 R
  f     51    IG-MEC      intermediate   pT2N2bM0    +++            39                 +++             34                  132 M
  m     57    IG-MEC      intermediate   pT1NxM0     +++            44                 +++             40                  94 R
  m     72    IG-MEC      intermediate   pT1NxM0     ++             25                 ++              23                  31 NED
  f     74    IG-MEC      intermediate   pT1NxM0     ++             21                 ++              21                  95 NED
  f     80    IG-MEC      intermediate   pT3NxM0     ++             26                 ++              24                  97 NED
  m     56    HG-MEC      high           pT2N0M0     +++            36                 +++             35                  131 R
  f     32    HG-MEC      high           pT4NxM0     ++             25                 ++              25                  200 NED
  f     33    HG-MEC      high           pT1NxM0     ++             22                 ++              21                  23 NED
  m     51    HG-MEC      high           pT2N0M0     ++             24                 ++              22                  72 NED
  m     60    HG-MEC      high           pT3N0M0     ++             26                 ++              23                  34 NED
  f     56    CXPA        \-             pT2NxM0     ++             23                 ++              21                  23 NED
  f     24    CXPA        \-             pT2N0M0     ++             26                 ++              25                  97 NED
  m     42    CXPA        \-             pT1N0M0     +++            42                 ++              29                  55 R,N
  m     43    CXPA        \-             pT3N0M0     ++             23                 ++              21                  63 NED
  m     72    CXPA        \-             pT2NxM0     ++             22                 ++              22                  166 NED
  f     28    PA          \-             \-          \+             13                 \+              11                  12 NED

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Clinical and pathological features of the study population of SM, ordered by Breslow thickness. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Breslow      TNM Stage   WS CAF-1 p60   WS CAF-1 p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- ------------ ----------- -------------- ------------------ --------------- ------------------- ----------
  m     39    MM          ≤/=1.00      IA          +++            37                 +++             34                  6 R
  f     36    MM          ≤/=1.00      IB          +++            33                 ++              29                  4 N
  m     56    MM          ≤/=1.00      IB          ++             24                 ++              23                  2 NED
  m     35    MM          ≤/=1.00      IB          ++             23                 ++              21                  7 NED
  m     41    MM          ≤/=1.00      IB          ++             25                 ++              23                  7 NED
  f     32    MM          ≤/=1.00      IA          ++             27                 ++              22                  6 NED
  f     66    MM          1.01--2.00   IB          +++            38                 +++             35                  12 N
  f     47    MM          1.01--2.00   IIA         +++            55                 +++             45                  12 N,M,D
  f     39    MM          1.01--2.00   IB          +++            46                 +++             42                  9 N
  f     37    MM          1.01--2.00   IIA         +++            51                 +++             47                  7 R,N
  f     43    MM          1.01--2.00   IB          ++             23                 ++              21                  9 NED
  m     22    MM          1.01--2.00   IA          ++             24                 ++              22                  4 NED
  m     37    MM          1.01--2.00   IA          ++             26                 ++              20                  3 NED
  m     43    MM          1.01--2.00   IB          +++            40                 +++             39                  7 N
  m     45    MM          2.01--4.00   IIIC        +++            49                 +++             46                  11 N,M,D
  m     47    MM          2.01--4.00   IIB         +++            39                 ++              28                  10 N
  f     42    MM          2.01--4.00   IIA         +++            43                 +++             37                  9 N,M,D
  f     46    MM          2.01--4.00   IIB         +++            40                 +++             39                  3 N
  f     81    MM          2.01--4.00   IIA         +++            45                 +++             41                  2 M
  m     32    MM          2.01--4.00   IIB         +++            47                 +++             41                  3 N,M
  f     50    MM          2.01--4.00   IIA         ++             25                 ++              22                  11 NED
  m     38    MM          2.01--4.00   IIA         ++             25                 ++              24                  3 NED
  f     56    MM          2.01--4.00   IIA         ++             24                 ++              23                  13 NED
  m     21    MM          2.01--4.00   IIB         ++             27                 ++              22                  14 NED
  f     55    MM          \>4.00       IIC         ++             22                 ++              21                  14 NED
  m     54    MM          \>4.00       IIB         ++             21                 ++              20                  12 NED
  m     35    MM          \>4.00       IIC         ++             26                 ++              24                  2 NED
  f     38    MM          \>4.00       IIC         +++            44                 +++             38                  1 N
  f     52    MM          \>4.00       IIC         +++            38                 ++              29                  2 R,M,D
  m     44    MM          \>4.00       IIC         +++            49                 +++             48                  12 N

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Clinical and pathological features of the study population of LSCC, ordered by grading. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Grading   TNM Stage   WS CAF-1 p60   WS CAF-1 p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- --------- ----------- -------------- ------------------ --------------- ------------------- ---------
  m     38    SCC         G1        II          ++             22                 ++              21                  187 NED
  m     66    SCC         G1        IVA         +++            42                 +++             33                  184 M
  m     53    SCC         G1        IVA         ++             27                 ++              22                  182 NED
  m     68    SCC         G1        III         ++             23                 ++              20                  181 NED
  m     70    SCC         G1        II          ++             22                 ++              21                  180 NED
  m     70    SCC         G1        I           ++             24                 ++              23                  82 NED
  m     53    SCC         G1        I           ++             25                 ++              24                  189 NED
  m     76    SCC         G2        II          ++             26                 ++              22                  188 NED
  m     65    SCC         G2        I           ++             21                 ++              20                  186 NED
  m     75    SCC         G2        IVA         ++             27                 +++             31                  182 NED
  m     72    SCC         G2        IVA         ++             23                 ++              21                  58 NED
  m     52    SCC         G2        I           +++            40                 +++             38                  45 M
  m     61    SCC         G2        II          ++             22                 ++              21                  39 NED
  m     65    SCC         G2        IVA         ++             25                 +++             31                  38 NED
  m     57    SCC         G3        IVA         ++             26                 ++              25                  69 NED
  m     73    SCC         G3        III         ++             25                 ++              24                  66 NED
  m     62    SCC         G3        III         ++             23                 ++              22                  45 NED
  m     63    SCC         G3        IVA         ++             23                 ++              22                  186 NED
  m     58    SCC         G3        IVA         ++             25                 ++              24                  185 NED
  m     60    SCC         G3        I           ++             24                 ++              23                  153 NED
  m     75    SCC         G3        II          ++             22                 ++              21                  65 NED
  m     52    SCC         G3        IVB         +++            39                 +++             37                  187 M
  m     66    SCC         G3        IVA         ++             23                 ++              21                  183 NED
  m     59    SCC         G3        III         ++             21                 ++              20                  181 NED
  m     75    SCC         G3        IVA         ++             25                 ++              23                  124 NED
  m     58    SCC         G3        IVA         ++             27                 ++              26                  69 NED
  m     71    SCC         G3        IVA         ++             24                 ++              22                  53 NED
  m     50    SCC         G3        IVA         ++             26                 ++              24                  119 NED
  m     72    SCC         G3        III         +++            38                 +++             35                  180 M
  m     65    SCC         G3        IVA         ++             28                 ++              27                  124 NED

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Clinical and pathological features of the study population of SSCC, ordered by grading. Correlation with CAF-1 p60 expression.

  Sex   Age   Histotype   Grading   TNM Stage   WS CAF-1/p60   WS CAF-1/p60 (%)   TMA CAF-1 p60   TMA CAF-1 p60 (%)   F-up
  ----- ----- ----------- --------- ----------- -------------- ------------------ --------------- ------------------- ---------
  m     76    SCC         G1        I           ++             23                 ++              21                  223 NED
  m     73    SCC         G1        I           ++             24                 ++              23                  222 NED
  f     86    SCC         G1        I           ++             22                 ++              20                  221 NED
  m     72    SCC         G1        II          ++             26                 ++              22                  218 NED
  m     36    SCC         G1        II          ++             24                 ++              23                  209 NED
  f     95    SCC         G1        II          ++             22                 ++              21                  122 NED
  m     80    SCC         G1        II          ++             26                 ++              23                  69 NED
  m     55    SCC         G1        I           ++             24                 ++              23                  69 NED
  f     67    SCC         G2        II          ++             22                 ++              22                  210 NED
  m     49    SCC         G2        II          +++            36                 ++              29                  207 R,M
  f     78    SCC         G2        IV          ++             25                 ++              24                  147 NED
  f     83    SCC         G2        I           ++             26                 ++              23                  127 NED
  m     80    SCC         G2        I           ++             24                 ++              24                  126 NED
  f     68    SCC         G2        II          ++             23                 ++              23                  125 NED
  m     79    SCC         G2        II          ++             22                 ++              21                  90 NED
  f     51    SCC         G2        I           ++             26                 ++              21                  24 NED
  m     63    SCC         G2        I           ++             24                 ++              23                  69 NED
  m     59    SCC         G2        II          ++             26                 ++              25                  70 NED
  m     85    SCC         G2        I           ++             21                 ++              20                  66 NED
  m     32    SCC         G3        IV          ++             22                 ++              21                  213 NED
  m     67    SCC         G3        II          +++            41                 +++             40                  212 R
  f     71    SCC         G3        I           ++             22                 ++              21                  209 NED
  f     76    SCC         G3        I           ++             27                 ++              25                  201 NED
  f     72    SCC         G3        IV          ++             23                 ++              22                  189 NED
  m     67    SCC         G3        II          ++             24                 ++              23                  155 NED
  f     73    SCC         G3        II          ++             22                 ++              21                  12 NED
  f     42    SCC         G3        III         ++             21                 ++              20                  12 NED
  m     74    SCC         G3        II          ++             27                 ++              26                  68 NED
  f     77    SCC         G3        II          ++             24                 ++              24                  64 NED
  m     66    SCC         G3        II          ++             25                 ++              24                  216 NED

NED: not evidence of disease; R: relapse; M: distant metastasis; D: death for disease.

###### 

Whole tissue sections and TMA concordance, *K*-coefficients grouped by pathology. Cohen's weighted kappa statistic, standard error and 95% confidence intervals are shown.

                        OSCC         PC           SM           SGT          LSCC         SSCC
  --------------------- ------------ ------------ ------------ ------------ ------------ ------------
  ***K*-coefficient**   0.8018       0.8148       0.8018       0.8529       0.8696       0.8076
  **S.E.**              0.07361111   0.08611111   0.07361111   0.07638889   0.08819444   0.14513889
  **95% CI**            0.593--1     0.571--1     0.593--1     0.627--1     0.620--1     0.374--1
